Morfină Zentiva (Morphine Hydrochloride Trihydrate)

Morphine hydrochloride binds to μ‑opioid receptors in the brain and spinal cord, inhibiting the release of pain‑transmitting neurotransmitters. This reduces neuronal excitability, leading to decreased perception of pain and a calming, sedative effect.

The dose of Morfină Zentiva is individualized by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, age, organ function, and overall clinical condition. No fixed regimen is provided here.

Safety data for morphine in pregnancy and lactation are limited. Use only if the potential benefit justifies the potential risk to the fetus or infant, and always under close medical supervision.

To request Morfină Zentiva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both morphine and fentanyl are potent opioids, but morphine has a longer onset and duration when given subcutaneously, while fentanyl is more lipophilic and often used in transdermal or intravenous forms. Choice depends on clinical context, required speed of analgesia, and patient‑specific factors.

Store Morfină Zentiva at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct sunlight, and avoid freezing.

Morfină Zentiva is supplied as a sterile injectable solution for subcutaneous injection. Administration is performed by a qualified healthcare professional using aseptic technique, typically in a clinical setting.

The most serious risks include respiratory depression, severe hypotension, anaphylactic reactions, adrenal insufficiency, seizures, and the potential for dependence or addiction. Immediate medical attention is required if any of these occur.

Patients with known hypersensitivity to morphine or any component of the formulation, those with uncontrolled respiratory disease, severe asthma, or significant head injury should avoid Morfină Zentiva. It is also contraindicated in individuals taking MAO inhibitors within the past 14 days.